louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01626911: Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Pancreatitis
Keywords: severe acute pancreatitis;
continuous regional arterial infusion;
low molecular weight heparin
Lead sponsor: Nanjing University School of Medicine
Sponsor class: OTHER
First posted: 2012-06-25
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Our animal studies found that continuous regional arterial infusion (CRAI in the celiac trunk) of low molecular weight heparin (LMWH) could alleviate inflammation, improve global hemodynamics and restore organ function in a porcine model of severe acute pancreatitis (SAP,unpublished).

In this study, the investigators aim to evaluate the effects of CRAI of LMWH in the treatment of SAP patients. The investigators suppose CRAI could help improve the outcomes of these patients.


Eligibility criteria: Inclusion Criteria:

* Symptoms and signs of severe acute pancreatitis according to Atlanta criteria
* Within 3 days from the onset of the disease
* Available for interventional treatment(not sensible to radiocontrast agent)

Exclusion Criteria:

* Pregnant pancreatitis
* Receiving surgery or aspiration before;need of early surgery
* Patients with coagulation disorders

Primary outcomes:
measure: coagulation related complications
timeFrame: 14 days after the placement of celiac trunk catheter
measure: Pancreatic infection
timeFrame: 28 days
Secondary outcomes:
measure: pancreatic necrosis
timeFrame: 28 days
measure: ICU duration
timeFrame: Participants will be followed until the date of discharge from the ICU,assessed up to 6 weeks. Patients who die during hospitalization are excluded from this measurement.
measure: Hospital duration
timeFrame: Participants will be followed until the date of discharge from the hospital,assessed up to 3 months. Patients who die during hospitalization are excluded from this measurement.
measure: Mortality
timeFrame: Participants will be followed until the date of discharge or the date of death from any cause, whichever came first, assessed up to 3 months
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, China
state: Jiangsu
Study officials:
affiliation: Jinling Hospital, School of Medicine, Nanjing University
name: Weiqin Li, Dr
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lu XS, Qiu F, Li YX, Li JQ, Fan QQ, Zhou RG. Effect of lower-molecular weight heparin in the prevention of pancreatic encephalopathy in the patient with severe acute pancreatitis. Pancreas. 2010 May;39(4):516-9. doi: 10.1097/MPA.0b013e3181c3c954.
Clinical trial NCT03604211: SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience
Official title: Predictive Factors for the Benefit of Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer Recurrent
Prostate Cancer
Lymph Node Metastases
Lead sponsor: Kantonsspital Graubuenden
Sponsor class: OTHER
Collaborators: name: Swiss Group for Clinical Cancer Research
First posted: 2018-07-27
Enrollment: 25
Sex: MALE
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: single-Institution cohort of male patients 18-85 years of age, with recurrent prostate cancer after radical prostatectomy in 1-3 lymphnodes, prospectively registered in a local institutional database

Brief summary: Single-institution retrospective analysis for predictive factors of prostate cancer patients presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.

Detailed description: Single-institution retrospective analysis of consecutive prostate cancer patients after definitive primary treatment, without local recurrence, presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.

Endpoints of interest are biochemical response rate (defined as a reduction by at least 10% of the initial PSA value), time to biochemical recurrence (TBR) (defined as the time interval from SBRT until second PSA rise), and time interval between SBRT and ADT start. Univariate analysis is used to identify prognostic factors.

Eligibility criteria: Inclusion Criteria:

* histologically proven diagnosis of prostate cancer
* Radical prostatectomy (± salvage radiotherapy)
* PSA relapse (defined by two consecutive rising PSA values \>0.2 ug/l)
* one to three lymphnodes positive on Choline-PET
* no recurrence in prostatic bed on Choline-PET
* WHO performance status of 0-1
* no previous chemotherapy or ADT for prostate cancer.

Exclusion Criteria:

* primary treatment for prostate cancer by RT or brachytherapy
* bone (M1b) metastases
* visceral (M1c) metastases
* any symptomatic nodal lesion

Primary outcomes:
measure: time to biochemical recurrence
timeFrame: 18 months
Secondary outcomes:
measure: biochemical response rate
timeFrame: 18 months
measure: time interval between SBRT and ADT start
timeFrame: 18 months
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: Juergen Curschmann
Study officials:
affiliation: Kantonsspital Graubuenden
name: Daniel R Zwahlen, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03636711: Antibiotic Stewardship in Infectious Disease Departement
Official title: Adherence to Anti-infectious Treatment Protocols in Emergencies and Short-term Hospitalization at the Infectious Disease Department"
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infectious Disease
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2018-08-17
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who present a infectious syndrom

Brief summary: Consensual antibiotic protocols have been developed and validated locally by infectious disease specialists, internists and emergency physicians, in order to encourage their compliance. A preliminary study was conducted from June 2015 to February 2016, including 622 patients admitted to the emergency department for infectious syndrome such as /

* Pneumoniae
* Urinary tract infection
* Cellulitis
* Meningitis
* Malaria
* Febrile neutropenia
* Febrile acute diarrhea
* Fever back to the tropics
* Angina
* sexually transmitted infection This prospective study will observe and analyze the adherence of prescribers to these protocols. With description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols. In order to limit the length of stay and reduce the cost of hospitalization..

Detailed description: Consensual antibiotic protocols have been developed and validated locally by infectious disease specialists, internists and emergency physicians, in order to encourage their compliance. A preliminary study was conducted from June 2015 (setting up protocols) to February 2016, including 622 patients admitted to the emergency department for infectious syndrome such as /

* Pneumoniae
* Urinary tract infection
* Cellulitis
* Meningitis
* Malaria
* Febrile neutropenia
* Febrile acute diarrhea
* Fever back to the tropics
* Angina
* sexually transmitted infection This prospective study will observe and analyze the adherence of prescribers to these protocols. With description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols. In order to limit the length of stay and reduce the cost of hospitalization..

Eligibility criteria: Inclusion Criteria:

* Patient admitted to emergency for infectious syndrome
* Patient \> 18 years old.
* Patient who accept to have his medical records reviewed for research.

Exclusion Criteria:

* Patient \< 18 years old.

Primary outcomes:
measure: List of Antibiotic treatment
timeFrame: up to 12 weeks
measure: Adverse events
timeFrame: up to 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Assistance Publique Des Hopitaux de Marseille
state: Paca
Study officials:
affiliation: APHM
name: EMILIE GARRIDO PRADALIE
role: STUDY_DIRECTOR
References:
Clinical trial NCT02773511: Multi-center Study on Surgical or Non-surgical Treatment for Children Type 1 Humeral Condyle Fracture
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Treatment for Type I Humeral Condyle Fracture
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2016-05-16
Enrollment: 240
Sex: ALL
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study evaluates the effectiveness of surgical or non-surgical treatment for children type 1 humeral condyle fracture.Half of the participants receive surgical treatment and the other half receive non-surgical treatment


Eligibility criteria: Inclusion Criteria:

Children Type 1 humeral Condyle Fracture，Fracture displacement less than 2mm

Exclusion Criteria:

Other type humeral Condyle Fracture

Primary outcomes:
measure: Fracture displacement rate
timeFrame: 1 months
measure: Fracture healing rate
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03935828: Effect of Topical Sinonasal Antibiotics
Official title: Effect of Topical Sinonasal Antibiotics in Post-Surgical Patients With an Acute Exacerbation of Chronic Rhinosinusitis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Chronic Rhinosinusitis (Diagnosis)
Antibiotic Side Effect
Keywords: chronic rhinosinusitis
topical sinonasal antibiotics
randomized controlled trial
Lead sponsor: United States Naval Medical Center, San Diego
Sponsor class: FED
First posted: 2019-05-02
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized to oral versus topical antibiotics
Primary purpose: TREATMENT

Brief summary: In this study, patients who have had previous endoscopic sinus surgery and present with an acute exacerbation of chronic rhinosinusitis will be offered endoscopic-guided, culture-directed antibiotic therapy. They will then be randomized to receive oral or intranasal topical antibiotics. Both of these are considered standard of care, but there is some limited data suggesting superiority of topical antibiotics especially if guided by culture and in patients who have undergone previous surgery. However, a study that directly compares the two has not been published. Modified Lund-Kennedy endoscopic finding scores and subjective SNOT-22 questionnaires will be collected before and at 3-4 weeks after treatment. Medication-related sided effects will be noted and analyzed. After 6-8 month follow-up, we will analyze the rate of recurrence of exacerbations, need for further antibiotics, need for revision surgery, and SNOT-22 scores based on oral versus topical antibiotic treatment. Our objective is to evaluate both short and long-term response to both oral and topical administration of antibiotics in this patient population in order to determine if either route of administration is superior to the other.


Eligibility criteria: Inclusion Criteria:

* Patients who have documented CRS refractory to initial medical management and have undergone sinus surgery (opening of at least one sinus ostium, exclusive of sole balloon dilation), and those with an acute exacerbation of CRS with sinus mucopurulence on exam.

Exclusion Criteria:

* Patients less than 18 years of age, and those that have taken an antibiotic regimen in the previous 2 weeks before culture.

Primary outcomes:
measure: SNOT-22
timeFrame: Baseline, 3-4 weeks after initiation, and at 6-8 months
Secondary outcomes:
measure: Modified Lund-Kennedy Score
timeFrame: Baseline and 3-4 weeks after initiation
measure: Antibiotic Side Effect Questions
timeFrame: 3-4 weeks after initiation
measure: Final Questions
timeFrame: 6-8 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03933228: Analgesia for Clavicular Fracture and Surgery
Official title: Ultrasound-Guided Combined Interscalene-Cervical Plexus Versus Combined Supraclavicular-Cervical Plexus Block for Surgical Anesthesia in Clavicular Fractures: A Retrospective Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Clavicular Fractures
Keywords: Combined Interscalene-Cervical Plexus Block
Combined Supraclavicular-Cervical Plexus Block
Lead sponsor: Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
Sponsor class: OTHER
First posted: 2019-05-01
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 150

Brief summary: Compared efficacy of ultrasound-guided combined interscalene-cervical plexus versus combined supraclavicular-cervical plexus block for surgical anesthesia in clavicular fractures.

Detailed description: The primary objective of this study was to compare the effectiveness of ultrasound-guided combined interscalene-cervical plexus versus combined supraclavicular-cervical plexus block for surgical anesthesia in clavicular fractures.The hypothesis of this study was that the supraclavicular-cervical plexus block could provide better anesthesia with less anesthesia related complications.

Eligibility criteria: Inclusion Criteria:

* Surgery of the clavicular fractures under combined cervical plexus plus brachial plexus block
* Urgent or planned surgery

Exclusion Criteria:

* Refused to sign informed consent
* Pregnant women
* Allergic to the local anesthetic

Primary outcomes:
measure: Block success rate
timeFrame: At time 15 minutes after the block
Secondary outcomes:
measure: Acute complications
timeFrame: At the end of surgery immediately
Other outcomes:
Locations:
city: Cangzhou
country: China
facility: Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
state: Hebei
Study officials:
affiliation: Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
name: Ruizhao Lv, M.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05040828: Early Intervention in Allergic Patients
Official title: Early Intervention With Leukotriene Receptor Antagonists in Patients With Grass Pollinosis: Effects on Clinical Symptoms and Allergic Inflammation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Allergic Rhinitis Due to Weed Pollen
Montelukast
Lead sponsor: Beijing Tongren Hospital
Sponsor class: OTHER
First posted: 2021-09-10
Enrollment: 59
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: As many as 250 million people suffer from allergic rhinitis in China, which has a large population, early use of drugs may help better control the symptoms.This study aimed to investigate the effects of early interventional treatment with the leukotriene receptor antagonist (LTRA) montelukast on seasonal allergic rhinitis.


Eligibility criteria: Inclusion Criteria:

* patients showed distinct nasal symptoms (rhinorrhea, congestion, itching, and sneezing), and demonstrated sensitization to one of the grass pollen allergens (Artemisia, Chenopodium, and Humulus scandens) with an immunoglobulin (Ig) E ≥ 0.7 IU/mL, measured using the Pharmacia UniCAP system (Thermo Fisher Scientific China Co., Ltd., Shanghai, China).
* had not received any therapies for AR or antibiotics for at least 4 weeks before their outpatient clinic visit prior to the study
* all of the subjects in the study reside in Beijing.

Exclusion Criteria:

* Patients diagnosed with bronchial asthma, suffering from rhinitis outside the pollen season, chronic sinusitis, deviated nasal septum, using specific immunotherapy, or participating in another drug efficacy trial during the 4-week period preceding the study.
* pregnant women and minors

Primary outcomes:
measure: The change of subjective AR symptoms
timeFrame: baseline, visit 1: 2 weeks prior to the high weed pollen stage, visit 2: high weed pollen stage, visit 3: 2 weeks after the high weed pollen stage.
Secondary outcomes:
measure: The change of objective examination: nasal function
timeFrame: baseline, visit 1: 2 weeks prior to the high weed pollen stage, visit 2: high weed pollen stage, visit 3: 2 weeks after the high weed pollen stage.
measure: The change of cytokine expression
timeFrame: baseline, visit 1: 2 weeks prior to the high weed pollen stage, visit 2: high weed pollen stage, visit 3: 2 weeks after the high weed pollen stage.
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tongren Hospital
state: Beijing
Study officials:
affiliation: Beijing Institute of Otolaryngology
name: Zhang Luo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06502028: Video Laryngeal Mask Versus Endotracheal Tube Undergoing Laparoscopic Cholecystectomy Surgery
Official title: Video Laryngeal Mask Versus Endotracheal Tube in Patients Undergoing Laparoscopic Cholecystectomy Surgery Under General Anesthesia: a Prospective Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cholecystitis
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2024-07-15
Enrollment: 102
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to investigate the effectiveness of using a video laryngeal mask for airway management in patients undergoing laparoscopic cholecystectomy.

Detailed description: The investigators will compare the time required to secure the airway when inserting a video laryngeal mask (LMA) versus performing endotracheal intubation.

Eligibility criteria: Inclusion Criteria:

* Patients over 19 years old
* Patients planned for elective laparoscopic cholecystectomy

Exclusion Criteria:

* High risk of aspiration (e.g. gastro-esophageal reflux disease, hiatus hernia, pregnancy, history of gastrectomy)
* Difficult airway (e.g. limitation of mouth opening, limitation of neck extension, oropharyngeal pathology)
* Obesity (BMI \> 30 kg/m2)
* Tooth mobility

Primary outcomes:
measure: Time required for VLMA insertion or intubation
timeFrame: After induction of anesthesia, before the operation starts.
Secondary outcomes:
measure: Number of trials
timeFrame: After induction of anesthesia, before the operation starts.
measure: Peak airway pressure
timeFrame: After video laryngeal mask airway insertion or intubation, before extubation
measure: Minute ventilation
timeFrame: After video laryngeal mask airway insertion or intubation, before extubation
measure: End tidal carbon dioxide
timeFrame: After video laryngeal mask airway insertion or intubation, before extubation
measure: Oropharyngeal leak pressure
timeFrame: After video laryngeal mask airway insertion or intubation, before extubation
measure: Traces of blood on airway device after extubation
timeFrame: After extubation, before transfer to PACU
measure: Postoperative sore throat
timeFrame: 1 hour after end of operation
measure: Postoperative sore throat
timeFrame: 24 hours after end of operation
measure: Postoperative hoarseness
timeFrame: 1 hour after end of operation
measure: Postoperative hoarseness
timeFrame: 24 hours after end of operation
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Hansol KIM, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00004828: Liothyronine in Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan Procedure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Tricuspid Atresia
Heart Defects, Congenital
Keywords: cardiovascular and respiratory diseases
heart defects
rare disease
Lead sponsor: FDA Office of Orphan Products Development
Sponsor class: FED
Collaborators: name: Children's Hospital and Health Center
First posted: 2000-02-25
Enrollment: 28
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: OBJECTIVES: I. Determine the pharmacokinetics of exogenous liothyronine administered in children undergoing the modified Fontan procedure.

II. Determine the liothyronine supplementation dose that counters the fall in serum liothyronine concentrations and provides the greatest potential myocardial benefit after the modified Fontan procedure.

III. Evaluate the potential toxicity of exogenous liothyronine administered in children undergoing a modified Fontan procedure.

Detailed description: PROTOCOL OUTLINE: This is a randomized, placebo controlled, dose escalation study.

Initially, patients are randomized to receive either 1 of 3 different dosages of liothyronine or placebo after undergoing the Fontan procedure. If no unacceptable toxicity is observed in this group, a third dose level of liothyronine is added to the randomization. A total of 7 patients are enrolled at each dose level. All randomized study drugs are administered by continuous infusion over 1 hour after surgery.

Cardiac function is assessed 5 days after surgery.

Eligibility criteria: * Single ventricle congenital cardiac malformation
* Must undergo modified Fontan procedure
* No concurrent medications known to interfere with thyroid metabolism including propranolol and amiodarone
* No hepatic dysfunction
* No renal dysfunction
* No pre-existing thyroid dysfunction

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Children's Hospital and Health Center
name: Richard Mainwaring
role: STUDY_CHAIR
References: